Biogen Inc.

NASDAQ Global Select
Back to all articles
Bearish -65

Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS

📅 Biogen reports Q2 2026 earnings on July 29 before the opening bell.

💰 Consensus EPS estimate is $2.10 with revenue expected at $2.46 billion.

📉 Analysts project a 61.6% year-over-year EPS decline compared to Q2 2025's $5.47 per share.

📊 Revenue is forecast to contract by 7.2% compared to the prior year's $2.65 billion.

🤔 EPS forecasts show wide dispersion from -$21.10 to $4.26, signaling high uncertainty.

📉 Analyst estimates have collapsed 51.7% over the last 90 days from a high of $4.35.

🏥 Key focus areas include legacy franchise performance against biosimilars and newer therapy uptake.

🚀 Investors will watch for pipeline updates on late-stage assets and regulatory submissions.

💸 Management's H2 guidance will determine if current pressures are temporary or structural.

📈 Operating margin trends will reveal the company's ability to defend profitability under revenue pressure.

Risk Factors
  • Wall Street expects a sharp earnings decline with consensus EPS of $2.10, down significantly from the prior year.
  • Analyst estimates have collapsed 51.7% over the last 90 days, reflecting deteriorating sentiment and fundamental headwinds.
  • The company faces a projected 61.6% year-over-year EPS drop and 7.2% revenue contraction compared to Q2 2025.
  • Wide dispersion in EPS forecasts ranging from a $21.10 loss to $4.26 earnings signals considerable uncertainty about profitability.
  • Biogen is likely facing erosion in mature franchises, slower uptake of new therapies, or intensifying competition from generics and biosimilars.
  • The magnitude of implied margin compression suggests potential pricing headwinds or elevated spending on clinical development.
Full Analysis
Biogen Inc. (BIIB) is set to report second-quarter 2026 earnings on July 29, with Wall Street anticipating a sharp decline in results. Analyst consensus estimates EPS at $2.10 and revenue at $2.46 billion, though the EPS forecast shows significant dispersion ranging from a loss of $21.10 to $4.26, indicating high uncertainty regarding the company's near-term profitability. The expected performance represents a severe downturn compared to the second quarter of 2025, when Biogen reported earnings of $5.47 per share on revenue of $2.65 billion. The consensus implies a year-over-year EPS drop of 61.6% and a revenue contraction of 7.2%, marking one of the company's most challenging comparisons in recent memory and signaling potential structural challenges beyond simple revenue softness. Analyst sentiment has deteriorated sharply over the past three months, with estimates collapsing 51.7% from $4.35 just 90 days ago to the current $2.10 consensus. This aggressive markdown suggests investors are digesting fundamental headwinds such as pipeline setbacks, competitive pressures, or margin compression, which will be scrutinized closely when management presents its results and guidance for the second half of the year.